Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

2.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK.

J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.

3.

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber.

Roux M, Devillier P, Yang WH, Montagut A, Abiteboul K, Viatte A, Zeldin RK.

J Allergy Clin Immunol. 2016 Aug;138(2):451-458.e5. doi: 10.1016/j.jaci.2016.03.039. Epub 2016 May 6.

PMID:
27289490
4.

Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.

Mascarell L, Rak S, Worm M, Melac M, Soulie S, Lescaille G, Lemoine F, Jospin F, Paul S, Caplier L, Hasséus B, Björhn C, Zeldin RK, Baron-Bodo V, Moingeon P.

Allergy. 2015 Apr;70(4):408-19. doi: 10.1111/all.12576.

PMID:
25631199
5.

Reply: To PMID 24388010.

Bergmann KC, Demoly P, Abiteboul K, Zeldin RK.

J Allergy Clin Immunol. 2015 Jan;135(1):288-9. doi: 10.1016/j.jaci.2014.09.021. Epub 2014 Oct 28. No abstract available.

PMID:
25441297
6.
7.

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.

Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, Nguyen H, Montagut A, Zeldin RK.

J Allergy Clin Immunol. 2014 Jun;133(6):1608-14.e6. doi: 10.1016/j.jaci.2013.11.012. Epub 2013 Dec 31.

PMID:
24388010
8.

Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.

Baron-Bodo V, Horiot S, Lautrette A, Chabre H, Drucbert AS, Danzé PM, Sénéchal H, Peltre G, Galvain S, Zeldin RK, Horak F, Moingeon P.

Clin Exp Allergy. 2013 Dec;43(12):1362-73. doi: 10.1111/cea.12187.

PMID:
24261946
9.

Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.

Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Soulié S, Zeldin RK.

Clin Exp Allergy. 2013 May;43(5):568-77. doi: 10.1111/cea.12100.

PMID:
23600548
10.

Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.

Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, Melac M, Zeldin RK.

J Allergy Clin Immunol. 2012 Dec;130(6):1327-34.e1. doi: 10.1016/j.jaci.2012.08.032. Epub 2012 Oct 31.

PMID:
23122534
11.

Automated telecommunication to obtain longitudinal follow-up in a multicenter cross-sectional COPD study.

Stewart JI, Moyle S, Criner GJ, Wilson C, Tanner R, Bowler RP, Crapo JD, Zeldin RK, Make BJ, Regan EA, For The Copdgene Investigators.

COPD. 2012 Aug;9(5):466-72. doi: 10.3109/15412555.2012.690010. Epub 2012 Jun 7.

12.

Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma.

Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK.

Ann Allergy Asthma Immunol. 2010 Dec;105(6):465-70. doi: 10.1016/j.anai.2010.09.011.

PMID:
21130385
13.

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.

Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK.

Pulm Pharmacol Ther. 2010 Oct;23(5):438-44. doi: 10.1016/j.pupt.2010.04.005. Epub 2010 Apr 21.

PMID:
20416390
14.

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.

Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK.

J Allergy Clin Immunol. 2010 Feb;125(2):383-9. doi: 10.1016/j.jaci.2009.11.022.

PMID:
20159249
15.

Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.

Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, Geba GP, Zeldin RK.

Clin Pediatr (Phila). 2009 Oct;48(8):859-65. doi: 10.1177/0009922809339054. Epub 2009 Jun 29.

PMID:
19564449
16.

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.

Massanari M, Kianifard F, Zeldin RK, Geba GP.

Allergy Asthma Proc. 2009 Sep-Oct;30(5):534-9. doi: 10.2500/aap.2009.30.3245. Epub 2009 May 22.

PMID:
19467177
17.

Treatment of chronic autoimmune urticaria with omalizumab.

Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK.

J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006.

PMID:
18774392
18.

Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity.

Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, Grant E, Zeldin RK, Edelman JM.

Ann Allergy Asthma Immunol. 2006 Jan;96(1):60-8.

PMID:
16440534
19.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Zeldin RK, Petruschke RA.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. Epub 2003 Dec 4. Review.

PMID:
14657084
20.

Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.

Katner HP, Paar DP, Nadler JP, Jensen EH, Wilson HM, Finn TS, Petruschke RA, Zeldin RK.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):483-7.

PMID:
12473836
21.

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.

Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):478-82.

PMID:
12473835
23.

The effect of a losartan-based treatment regimen on isolated systolic hypertension.

Cushman WC, Brady WE, Gazdick LP, Zeldin RK.

J Clin Hypertens (Greenwich). 2002 Mar-Apr;4(2):101-7.

24.
25.

Rats acquire spatial learning sets.

Zeldin RK, Olton DS.

J Exp Psychol Anim Behav Process. 1986 Oct;12(4):412-9.

PMID:
3772305

Supplemental Content

Loading ...
Support Center